126 related articles for article (PubMed ID: 3598899)
1. Mechanism of action of a novel antivasospasm drug, HA1077.
Asano T; Ikegaki I; Satoh S; Suzuki Y; Shibuya M; Takayasu M; Hidaka H
J Pharmacol Exp Ther; 1987 Jun; 241(3):1033-40. PubMed ID: 3598899
[TBL] [Abstract][Full Text] [Related]
2. Vasodilator actions of HA1077 in vitro and in vivo putatively mediated by the inhibition of protein kinase.
Asano T; Suzuki T; Tsuchiya M; Satoh S; Ikegaki I; Shibuya M; Suzuki Y; Hidaka H
Br J Pharmacol; 1989 Dec; 98(4):1091-100. PubMed ID: 2611484
[TBL] [Abstract][Full Text] [Related]
3. The effects of HA compound calcium antagonists on delayed cerebral vasospasm in dogs.
Takayasu M; Suzuki Y; Shibuya M; Asano T; Kanamori M; Okada T; Kageyama N; Hidaka H
J Neurosurg; 1986 Jul; 65(1):80-5. PubMed ID: 3712031
[TBL] [Abstract][Full Text] [Related]
4. Vasodilatory action of HA1004 [N-(2-guanidinoethyl)-5-isoquinolinesulfonamide], a novel calcium antagonist with no effect on cardiac function.
Asano T; Hidaka H
J Pharmacol Exp Ther; 1984 Oct; 231(1):141-5. PubMed ID: 6436469
[TBL] [Abstract][Full Text] [Related]
5. Cerebrovascular selectivity and vasospasmolytic action of the novel calcium antagonist (+/-)-(E)-1-(3-fluoro-6, 11-dihydrodibenz[b,e]oxepin-11-yl)-4-(3-phenyl-2-propenyl)-piperazine dimaleate in isolated cerebral arteries of the rabbit and dog.
Minato H; Hashizume M; Masuda Y; Fujitani B; Hosoki K
Arzneimittelforschung; 1997 Apr; 47(4):339-46. PubMed ID: 9150852
[TBL] [Abstract][Full Text] [Related]
6. Endothelin: a potential modulator of cerebral vasospasm.
Asano T; Ikegaki I; Satoh S; Suzuki Y; Shibuya M; Sugita K; Hidaka H
Eur J Pharmacol; 1990 Nov; 190(3):365-72. PubMed ID: 2272374
[TBL] [Abstract][Full Text] [Related]
7. Intracellular Ca++ antagonist, HA1004: pharmacological properties different from those of nicardipine.
Asano T; Hidaka H
J Pharmacol Exp Ther; 1985 May; 233(2):454-8. PubMed ID: 3999029
[TBL] [Abstract][Full Text] [Related]
8. Effects of isoquinoline derivatives, HA1077 and H-7, on cytosolic Ca2+ level and contraction in vascular smooth muscle.
Takizawa S; Hori M; Ozaki H; Karaki H
Eur J Pharmacol; 1993 Dec; 250(3):431-7. PubMed ID: 8112403
[TBL] [Abstract][Full Text] [Related]
9. The effects of an intracellular calcium antagonist HA 1077 on delayed cerebral vasospasm in dogs.
Shibuya M; Suzuki Y; Takayasu M; Asano T; Harada T; Ikegaki I; Satoh S; Hidaka H
Acta Neurochir (Wien); 1988; 90(1-2):53-9. PubMed ID: 3344625
[TBL] [Abstract][Full Text] [Related]
10. Blockade of intracellular actions of calcium may protect against ischaemic damage to the gerbil brain.
Asano T; Ikegaki I; Satoh S; Mochizuki D; Hidaka H; Suzuki Y; Shibuya M; Sugita K
Br J Pharmacol; 1991 Aug; 103(4):1935-8. PubMed ID: 1912980
[TBL] [Abstract][Full Text] [Related]
11. Effects of HA1077, a novel calciumantagonistic spasmolytic agent on intracerebral arterioles of rats.
Takayasu M; Dacey RG
Acta Neurochir (Wien); 1990; 103(1-2):67-70. PubMed ID: 2360470
[TBL] [Abstract][Full Text] [Related]
12. Inhibitor effects of diltiazem, nicardipine, nifedipine and verapamil on the norepinephrine-induced contractions of the canine saphenous vein in calcium-free medium.
Saïag B; Milon D; Bentue-Ferrer D; Allain H; Rault B; Van den Driessche J
Res Commun Chem Pathol Pharmacol; 1994 Mar; 83(3):255-69. PubMed ID: 8008975
[TBL] [Abstract][Full Text] [Related]
13. SR 33557, a novel calcium entry blocker. I. In vitro isolated tissue studies.
Polster P; Christophe B; Van Damme M; Houlliche A; Chatelain P
J Pharmacol Exp Ther; 1990 Nov; 255(2):593-9. PubMed ID: 1700816
[TBL] [Abstract][Full Text] [Related]
14. New pharmacological strategies in vascular diseases: a novel intracellular calcium antagonist, HA1077 (AT-877) and cerebral vasospasm.
Asano T; Hidaka H
Methods Find Exp Clin Pharmacol; 1990; 12(6):443-8. PubMed ID: 2087143
[No Abstract] [Full Text] [Related]
15. Cardiac and vascular effects of NZ-105, a novel dihydropyridine derivative, in vitro.
Masuda Y; Iwama T; Yamashita T; Sakai T; Hibi M; Tanaka S; Shigenobu K; Kasuya Y
Arch Int Pharmacodyn Ther; 1991; 314():57-73. PubMed ID: 1668604
[TBL] [Abstract][Full Text] [Related]
16. Possible prophylactic potential of HA1077, a Ca2+ channel antagonist and vasodilator, on chronic cerebral vasospasm.
Satoh S; Suzuki Y; Harada T; Ikegaki I; Asano T; Shibuya M; Sugita K; Hidaka H
Eur J Pharmacol; 1992 Sep; 220(2-3):243-8. PubMed ID: 1425995
[TBL] [Abstract][Full Text] [Related]
17. Effects of HA1077, a protein kinase inhibitor, on myosin phosphorylation and tension in smooth muscle.
Seto M; Sasaki Y; Hidaka H; Sasaki Y
Eur J Pharmacol; 1991 Mar; 195(2):267-72. PubMed ID: 1874276
[TBL] [Abstract][Full Text] [Related]
18. Tissue selectivity of the novel calcium antagonist sesamodil fumarate in isolated smooth muscles and cardiac muscles.
Nishimura K; Miyawaki N; Yamauchi H; Iso T
Arzneimittelforschung; 1990 Mar; 40(3):244-8. PubMed ID: 2112000
[TBL] [Abstract][Full Text] [Related]
19. Chronotropic, inotropic, and vasodilator actions of diltiazem, nifedipine, and verapamil. A comparative study of physiological responses and membrane receptor activity.
Millard RW; Grupp G; Grupp IL; DiSalvo J; DePover A; Schwartz A
Circ Res; 1983 Feb; 52(2 Pt 2):I29-39. PubMed ID: 6831652
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous assessment of effects of calmodulin antagonists and Ca++ channel blockers on the electrophysiological and mechanical characteristics in excised guinea-pig papillary muscles.
Koyama K; Himori N
Arch Int Pharmacodyn Ther; 1988; 292():141-56. PubMed ID: 3395166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
